Pilot Study assessing sildenafil effect on lung tumour blood flow

Pilot Study assessing sildenafil effect on lung tumour blood flow - sildenafil tumour perfusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31434

Enrollment

Registered

2007-11-09

Start date

2007-10-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer non-small cell lung cancer

Interventions

Administration of 50mg sildenafil.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2. WHO performance status 0-1 3. Adequate hematological, renal and hepatic functions a. total bilirubin =3cm 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Concurrent NTG, ritonivir, azoles, other P450 inhibitors 2. Concurrent anti-hypertensive or nitrate medications 3. Hypersensitivity to sildenafil/component of formulation 4. Contrast allergy 5. Hypotension

Design outcomes

Primary

Measure	Time frame
The baseline and post-sildenafil tumour perfusion will be compared using the Wilcoxon signed-rank test to assess any change in tumour perfusion.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)